Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5609676 | 0.83 | GAA (0.57) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL10821774 | 0.82 | ALDH1A1 (0.59) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL39559 | 0.81 | ALDH1A1 (0.63) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL284696 | 0.81 | ALDH1A1 (0.63) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL526641 | 0.79 | ALDH1A1 (0.61) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL39434 | 0.79 | HSPA5 (0.74) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL42656 | 0.79 | ALDH1A1 (0.64) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL9515058 | 0.78 | ALDH1A1 (0.55) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL22518766 | 0.78 | ALDH1A1 (0.55) | ALDH1A1GAATSHRLMNAKMT2A | |
| SCHEMBL4729051 | 0.78 | ALDH1A1 (0.65) | ALDH1A1GAATSHRLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992007830-A2 | OXINDOLE PEPTIDE ANTAGONISTS | PFIZER INC. (US) | 1992-05-14 | — | — | WO | claimed |
| CN-117377700-A | Plastomer with fast crystallization rate | 诺瓦化学品(国际)股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| US-5635534-A | 1-PHENYL-2-(2-PHENYLOXY OR THIO)-1-METHYLETHYL)AMINOETHANOL DERIVATIVES; ALDOSE REDUCTASE INHIBITORS; NONTOXIC; ANTIDIABETIC,-OBESITY,-LIPEMIC AND HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-06-03 | — | — | US | disclosed |
| US-5576340-A | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0543662-B1 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO CO (JP) | 1996-09-18 | — | — | EP | disclosed |
| US-5397821-A | Light and heat stabilizers, low volatility | ELFATOCHEM NORTH AMERICA, INC. (US) | 1995-03-14 | — | — | US | disclosed |
| US-5338853-A | N-(2,2,6,6-tetraalkyl-4-piperidinyl)amic acid hydrazides; contain light stabilizing group and heat stabilizing group | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1994-08-16 | — | — | US | disclosed |
| EP-0543662-A2 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992007830-A2 | OXINDOLE PEPTIDE ANTAGONISTS | PFIZER INC. (US) | 1992-05-14 | — | — | WO | disclosed |
| US-4234578-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
| US-4024249-A | FOR COMBATTING MICROORGANISMS | CIBA-GEIGY CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ALDH1A1 28/4885GAA 947/4885TSHR 1887/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | ALDH1A1 2128/4885GAA 818/4885TSHR 899/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | ALDH1A1 2128/4885GAA 818/4885TSHR 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.